Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMTX-101 Safety and PK Study in Healthy Volunteers and Pneumonia Patients
NCT05629741Phase 1Terminated
- Sponsor
- Clarametyx Biosciences
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CMTX-001 in community-acquired bacterial pneumonia (CAP) (5 arms), sponsored by Clarametyx Biosciences. Primary endpoints: Adverse Events, Serious Adverse Events and 1 more. Started Nov 2022; status: terminated.
02
Drugs
CMTX-001
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT05629741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629741.